Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Suzhou Zelgen Biopharmaceuticals Co.,Ltd clinical trials
The registry lists 83 studies whose lead sponsor is Suzhou Zelgen Biopharmaceuticals Co.,Ltd. 30 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Suzhou Zelgen Biopharmaceuticals Co.,Ltd studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd83 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 83. Browse all 83 →
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerRecruitingNCT06283719Phase 1/2
- ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07833839Phase 3
- ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularNot yet recruitingNCT07813572Phase 3
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07595913Phase 3
- Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract CarcinomaRecruitingNCT07099547Phase 2
- Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerRecruitingNCT07231445Phase 1
- Study of ZGGS34 in Participants With Advanced Solid TumorsRecruitingNCT07258121Phase 1/2
- Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT05978284Phase 1/2
- Study of ZGGS18 in Patients With Advanced Solid TumorsRecruitingNCT05584800Phase 1/2
- Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruitingNCT06903377Phase 1/2
- Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaRecruitingNCT06883526Phase 1/2
- Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid TumorsRecruitingNCT06938880Phase 1/2
- ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT07038096Phase 1/2
- Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerRecruitingNCT07189455Phase 3
- Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerRecruitingNCT07080216Phase 1/2
- Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsNot yet recruitingNCT07142837Phase 1/2
- A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung CancerRecruitingNCT06592638Phase 1
- Study of ZG006 in Participants With Neuroendocrine Prostate CancerNot yet recruitingNCT07024277Phase 2
- Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaRecruitingNCT06558227Phase 2
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.RecruitingNCT06440057Phase 1/2
- Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.RecruitingNCT06372626Phase 1/2
- Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical CarcinomaRecruitingNCT06241235Phase 1/2
- A Safety and Tolerability Study of JaktinibRecruitingNCT05279001Phase 1
- A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid TumoursRecruitingNCT06237413Phase 1/2
- A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisRecruitingNCT05676242Phase 3
- Study of ZG0895.HCl in Patients With Advanced Solid TumorsRecruitingNCT05877664Phase 1
- A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.Not yet recruitingNCT04971551Phase 2
- A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.RecruitingNCT06237400Phase 1/2
- An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingNCT05686629Phase 2
- A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingNCT05688839Phase 2
- A Study of ZG005 in Patients With Advanced Solid TumorsCompletedNCT06233292Phase 1/2
- Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)CompletedNCT05861128Phase 3
- Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)CompletedNCT05861102Phase 3
- rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)CompletedNCT04964284Phase 3
- rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid CancerCompletedNCT04447183Phase 2
- A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.Active, not recruitingNCT07565597Phase 1
- A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal TumorsTerminatedNCT04612712Phase 1/2
- Study of ZG005 in Patients With Advanced Solid TumorsActive, not recruitingNCT06927687Phase 2
- Study of ZGGS15 in Patients With Advanced Solid TumorsCompletedNCT05864573Phase 1
- A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisActive, not recruitingNCT05526222Phase 3
- Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedNCT05255237Phase 3
- Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedNCT05051761Phase 3
- A Phase 2 Study of Jaktinib in Participants With Moderate to Severe PsoriasisCompletedNCT04612699Phase 2
- Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary FibrosisCompletedNCT04312594Phase 2
- A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy ParticipantsCompletedNCT06193148Phase 1
- A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid TumorStatus unknownNCT06239298Phase 1/2
- Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibTerminatedNCT04211922Phase 2
- Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)WithdrawnNCT05702788Phase 2
- Jaktinib Hydrochloride Cream For Atopic DermatitisCompletedNCT04435392Phase 1/2
- Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone WithdrawalCompletedNCT04971473Phase 3